A shadow market for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Experimental Treatment Gaining Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Viewers are encouraged to message these accounts directly for source information, while also receiving promotional offers.
Active Commerce on Messaging Platforms
Separately, a robust market exists on Telegram, where communities with numerous of members share “before and after” photos, injection guides and claims of next-day British shipping. Sellers promote the drug there before directing customers to other platforms for transactions.
Understanding The Experimental Drug
This medication is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Medical Professionals Voice Worries
However, physicians and pharmacists have warned that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could lead to users injecting products of uncertain source.
Several experts said the demand for the experimental drug could be connected to the rising cost of licensed slimming treatments such as Mounjaro.
Regulatory Position and Implementation
Marketing retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed drug that must not be marketed or distributed for human use under the British medical regulations.
Several influencers try to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate medicines, advertising, and customer laws, potentially leading to fines, prosecution or imprisonment.
Platform Reaction and Material Removal
According to the social media company, the service has removed problematic content and banned associated hashtags and search suggestions. The company stated it was dedicated to keeping the service safe and investing in strengthening enforcement strategies.
Online Trading Activities
Investigations also found groups with up to 9,000 participants marketing retatrutide using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up groups with thousands of members, populated with photos of weight loss, glowing reviews and detailed instructions for mixing or administering at home.
Within minutes of joining one community, a vendor posted contact information, where the majority of transactions take place. The vendor provided an guidebook and guaranteed delivery within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None inquired about body mass, health issues or previous experience.
Product Details and Pricing
Inside these communities, messages display black plastic packages with Royal Mail labels, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how much time a injector should last, vendors give contradictory answers varying between a few weeks to “depends on your body”.
Platform Oversight and Security Actions
A representative for Telegram said it regularly monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“Individuals are administering substances they can’t verify. Even if the science behind this drug is sound, these online versions may not include what they advertise,” said Jason Murphy, the head of pharmacy at a pharmacy service.
A medical professional of an online medical service connected the surge in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs rising, individuals are using online platforms. But counterfeit injections are highly dangerous. You cannot know what’s contained or whether the environment they were made in was clean,” she explained.
Her team has already seen individuals injured by self-injection from unconfirmed suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.”
Producer Statement
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly investigational product not yet approved … may subject users to possibly significant medical dangers”.
